AI assistant
SOLESENCE, INC. — Director's Dealing 2022
Oct 26, 2022
33563_dirs_2022-10-26_a724e7bc-94f9-45bd-a45d-2f79573def1a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2022-10-24
Reporting Person: JANKOWSKI JESS (Director, President, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-10-24 | Common Stock | M | 2500 | $0.415 | Acquired | 61500 | Direct |
| 2022-10-24 | Common Stock | S | 2500 | $2.35 | Disposed | 59000 | Direct |
| 2022-10-25 | Common Stock | M | 800 | $0.415 | Acquired | 59800 | Direct |
| 2022-10-25 | Common Stock | S | 800 | $2.34 | Disposed | 59000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-10-24 | Common Stock (right to purchase) | $0.415 | M | 2500 | Disposed | 2023-02-14 | Common Stock (90000) | Direct |
| 2022-10-25 | Common Stock (right to purchase) | $0.415 | M | 800 | Disposed | 2023-02-14 | Common Stock (87500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1000 | Indirect |
| Common Stock | 59000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock (right to purchase) | $0.52 | 2024-02-13 | Common Stock (90000) | 90000 | Direct |
| Common Stock (right to purchase) | $0.44 | 2025-02-18 | Common Stock (81000) | 81000 | Direct |
| Common Stock (right to purchase) | $0.42 | 2026-02-23 | Common Stock (69000) | 69000 | Direct |
| Common Stock (right to purchase) | $0.68 | 2027-02-21 | Common Stock (81000) | 81000 | Direct |
| Common Stock (right to purchase) | $0.82 | 2028-05-23 | Common Stock (90000) | 90000 | Direct |
| Common Stock (right to purchase) | $0.51 | 2029-05-22 | Common Stock (16500) | 16500 | Direct |
| Common Stock (right to purchase) | $0.45 | 2027-06-18 | Common Stock (90000) | 90000 | Direct |
| Common Stock (right to purchase) | $4.17 | 2028-12-28 | Common Stock (90000) | 90000 | Direct |
Footnotes
F1: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
F2: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
F3: Subject to certain restrictions, beginning on this date, options vest in three equal installments.
F4: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
F5: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.